Active Awards Portfolio Dashboard
It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.
Filter Awards
| Disease |
Cell Type |
Therapeutic or Technology | Institution | Stage | Project Objective | Details |
|---|---|---|---|---|---|---|
| HIV/AIDS | Personalized cell therapy | COH |
 |
IND | ||
| Retinitis Pigmentosa | Donor cell therapy | jCyte |
 |
Clinical Trial, Phase 2 | ||
| Type 1 diabetes | Adult Stem Cell | Donor cell therapy | UCSF |
 |
Clinical Trial, Phase 1 or Phase 1/2 | |
|
HIV-related Lymphoma, HIV/AIDS |
Adult Stem Cell | Gene-modified, personalized cell therapy | UC Davis |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Alpha Thalassemia Major | Adult Stem Cell | Donor cell therapy | UCSF |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
COVID-19, Respiratory Disorders |
Adult Stem Cell | Donor cell therapy | Celularity Inc |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Cystinosis, Kidney Failure |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCSD |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Immune Disease, X-linked Chronic Granulomatous Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Sickle Cell Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
 |
Pre-IND/IDE or Equivalent | |
| Hearing Loss | Adult Stem Cell | Protein/peptide therapy | Stanford |
 |
Development Candidate, Proof of Concept | |
|
Brain Cancer, Breast Cancer |
Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Amyotrophic Lateral Sclerosis | Adult Stem Cell | Personalized cell therapy | BrainStorm |
 |
Clinical Trial, Phase 3 | |
| Skeletal/Smooth Muscle disorders | Adult Stem Cell | Small molecule therapy | Stanford |
|
Development Candidate | |
|
Beta Thalassemia, Sickle Cell Disease |
Adult Stem Cell | Diagnostic Test | CHORI |
|
Regulated Lab Test, Ready for Validation | |
| Blood Cancer | Adult Stem Cell | Gene-modified, donor cell therapy | Angiocrine |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Parkinson's Disease | Adult Stem Cell | Gene-modified, donor cell therapy | UCSF |
|
IND | |
| Multiple Myeloma | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Pre-IND/IDE or Equivalent | |
|
COVID-19, Respiratory Disorders |
Adult Stem Cell | Model system development | UCLA |
|
Development Candidate, Proof of Concept, Tool/Resources/Bottleneck | |
| Brain Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
|
IND | |
|
Pulmonary Hypertension, Vascular Disease |
Adult Stem Cell | Donor cell therapy | Cedars-Sinai |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Sickle Cell Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | Stanford |
|
IND | |
|
COVID-19, Respiratory Disorders |
Adult Stem Cell | Biologic | UCSD |
|
Development Candidate, Proof of Concept | |
| Brain Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
|
Development Candidate, Proof of Concept | |
| Age-related macular degeneration | Adult Stem Cell | Donor cell therapy | Stanford |
|
Pre-IND/IDE or Equivalent | |
| Brain Injury, hypoxic, ischemic | Adult Stem Cell | Donor cell therapy | Sanford-Burnham |
|
Pre-IND/IDE or Equivalent | |
| COVID-19 | Adult Stem Cell | Gene-modified, donor cell therapy | UCLA |
|
Development Candidate, Proof of Concept | |
| HIV/AIDS | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Development Candidate, Proof of Concept | |
| Ovarian Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
|
Development Candidate, Proof of Concept | |
| Spina Bifida | Adult Stem Cell | Donor cell therapy | UC Davis |
|
IND | |
| Kidney Failure | Adult Stem Cell | Donor cell therapy | Stanford |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Brain Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Severe Combined Immunodeficiency, X-linked (X-SCID) | Adult Stem Cell | Antibody | Jasper Therapeutics, Inc. |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Spinal Cord Injury | Adult Stem Cell | Donor cell therapy | UC Irvine |
|
Development Candidate | |
| Blood Cancer | Adult Stem Cell | Donor cell therapy | Angiocrine |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Vascular Disease | Adult Stem Cell | Biologic | UCSD |
|
Pre-IND/IDE or Equivalent | |
| COVID-19 | Adult Stem Cell | Donor cell therapy | UCSF |
|
Clinical Trial, Phase 2 | |
|
Arthritis, Osteoarthritis |
Adult Stem Cell | Small molecule therapy | Calibr |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Kidney Failure | Adult Stem Cell | Donor cell therapy | Medeor Therapeutics |
|
Clinical Trial, Phase 3 | |
|
Heart Disease, Danon Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCSD |
|
Development Candidate, Proof of Concept | |
| Osteonecrosis | Adult Stem Cell | Small molecule therapy | UC Davis |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Retinitis Pigmentosa | Adult Stem Cell | Donor cell therapy | Cedars-Sinai |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Amyotrophic Lateral Sclerosis | Adult Stem Cell | Gene-modified, donor cell therapy | Cedars-Sinai |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Sickle Cell Disease | Adult Stem Cell | Donor cell therapy | ExCellThera Inc. |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Blood Cancer, Bone Marrow Transplant and Viral Infection |
Adult Stem Cell | Donor cell therapy | CHLA |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Cancer | Adult Stem Cell | Gene-modified, donor cell therapy | UCLA |
|
Development Candidate, Proof of Concept | |
| Kidney Failure | Adult Stem Cell | Donor cell therapy | Stanford |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Severe Combined Immunodeficiency, X-linked (X-SCID) | Adult Stem Cell | Antibody | Stanford |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Sickle Cell Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Corneal Damage | Adult Stem Cell | Personalized cell therapy | UCLA |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Immune Disease, Severe Combined Immunodeficiency, X-linked (X-SCID) |
Adult Stem Cell | Gene-modified, personalized cell therapy | St. Jude |
|
Clinical Trial, Phase 1 or Phase 1/2 |
Pages
